Match!
Kevin B. Knopf
National Institutes of Health
40Publications
10H-index
1,011Citations
Publications 40
Newest
#1Charles L. BennettH-Index: 41
Last.Brian Y. ChenH-Index: 13
view all 17 authors...
Source
#1Kevin B. KnopfH-Index: 10
#2William Hrureshky (USC: University of South Carolina)
Last.Charles L. BennettH-Index: 41
view all 5 authors...
Source
The risk stratification of prostate cancer and breast cancer tumours from patients relies on histopathology, selective genomic testing, or on other methods employing fixed formalin tissue samples. However, static biomarker measurements from bulk fixed-tissue samples provide limited accuracy and actionability. Here, we report the development of a live-primary-cell phenotypic-biomarker assay with single-cell resolution, and its validation with prostate cancer and breast cancer tissue samples for t...
6 CitationsSource
#1Ashok C. ChanderH-Index: 2
#2Michael S. ManakH-Index: 2
Last.Kevin B. KnopfH-Index: 10
view all 6 authors...
Largely due to tumor heterogeneity, risk stratification of patients diagnosed with ductal carcinoma in situ (DCIS) of the breast remains a significant challenge. Management of DCIS is also problematic as we wish to personalize treatment of a patient’s tumor in order to avoid overtreatment of lower-risk lesions or undertreatment of DCIS that may recur or progress into invasive cancer. Matching treatment to the underlying severity of the illness is key to practicing cost-effective cancer care in a...
Source
#1Grannum R. Sant (Tufts University)H-Index: 41
#2Kevin B. KnopfH-Index: 10
Last.David M. Albala (SU: Syracuse University)H-Index: 47
view all 3 authors...
The promise of precision and personalized medicine is rooted in accurate, highly sensitive, and specific disease biomarkers. This is particularly true for cancer-a disease characterized by marked tumor heterogeneity and diverse molecular signatures. Although thousands of biomarkers have been described, only a very small number have been successfully translated into clinical use. Undoubtedly, there is need for rapid, quantitative, and more cost effective biomarkers for tumor diagnosis and prognos...
9 CitationsSource
#1Virginia NoxonH-Index: 4
#2Kevin B. KnopfH-Index: 10
Last.Charles L. BennettH-Index: 41
view all 15 authors...
Purpose:The US Food and Drug Administration (FDA) has approved epoetin and darbepoetin for chemotherapy-induced anemia (CIA). Approved epoetin and darbepoetin dosing schedules were three times per week and weekly, respectively, although off-label, less frequent scheduling was common. In 2004, 2007, and 2008, a US Food and Drug Administration Advisory Committees warned of risks associated with erythropoiesis-stimulating agents. During this period, lawsuits alleging illegal darbepoetin marketing p...
Source
e13081 Background: Patients with non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) are at risk for renal impairment as the median age at diagnosis is >65 years. Bendamustine is a bifunctional alkylating agent with efficacy via several pathways and a manageable toxicity profile in NHL and CLL. There has been no published research on its safety in renally impaired NHL and CLL patients. Methods: In this retrospective study of 2 electronic medical record databases from US outpatien...
#1Wayne SuH-Index: 1
#2Peter QuonH-Index: 1
Last.Ananth KadambiH-Index: 1
view all 11 authors...
6553 Background: To assess the cost-effectiveness of bendamustine plus rituximab (B-R) vs cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP‑R) for treatment-naive patients with MCL or IL from a US healthcare payer perspective. Methods: A discrete event simulation was developed for a mixed population of patients with MCL or IL. Two arms were simulated, each containing 1000 identical MCL or IL patients treated with B-R or CHOP-R. Input data for baseline characteristics, o...
1 Citations
e14576 Background: An increase in survival seen in recent years in patients with metastatic colorectal cancer (mCRC) has been attributed to improvements in treatments, including introduction of tar...
1 Citations
#1Kevin B. KnopfH-Index: 10
#2Michael Baum (UCL: University College London)H-Index: 31
Last.William J. M. HrusheskyH-Index: 41
view all 7 authors...
Surrogate endpoints are commonly used in clinical trials to get quicker results, but Kevin Knopf and colleagues show how they can lead to both medical and financial harm The rationale behind medical practice distils to three principles: maintaining health (wellbeing), improving quality of life, and extending length of life. For patients with incurable cancer, quality and length of life are of prime importance and should therefore be the primary outcome measures in all randomised clinical trials ...
2 CitationsSource
1234